Mercurius Capital Investment Limited (SG:5RF) has released an update.
Mercurius Capital Investment Limited has announced the signing of a memorandum of understanding with BioSpring Biomedical Co. Ltd., which could lead to a reverse takeover and integration of BioSpring’s stem cell expertise into the Company’s business portfolio. This strategic move aims to prevent the company’s removal from the SGX-ST Official List by fulfilling new listing requirements and is expected to enhance shareholder value and profitability. The board believes this acquisition will be in the best interests of the Company and its shareholders, with plans to seek shareholder approval in an upcoming extraordinary general meeting.
For further insights into SG:5RF stock, check out TipRanks’ Stock Analysis page.
